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Botulinum neurotoxins are highly potent toxins capable of rapid and speciﬁc interaction with the
presynaptic membrane. We have hypothesised that: (1) these neurotoxins possess an electric dipole
with the positive pole on receptor binding domain Hc-C and that (2) on approaching the negatively
charged presynaptic membrane, they reorient themselves and hit the membrane surface with Hc-C;
this electrostatic effect would contribute efﬁcient binding. Electrostatic calculations conﬁrm these
hypotheses and strongly indicate that electrostatics effects can play an important role in the unique
presynaptic membrane binding properties of these neurotoxins and generally on the interaction of
other plasma membrane protein ligands.
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
The most potent toxins known so far are seven presynaptic neu-
rotoxins, produced by bacteria of the genus Clostridium. They cause
the ﬂaccid paralysis and autonomic symptoms of botulism and,
therefore, are termed botulinum neurotoxins (BoNTs) [1]. They
are so potent (mouse LD50 in the range 1–5 ng/kg for the seven tox-
ins labelled with letters from A to G) because they are speciﬁc for
some peripheral nerve terminals and because they enter neurons
and cleave enzymatically the very essential SNARE proteins [2–5].
The crystallographic 3D structure of BoNT/A and BoNT/B has
been determined at high resolution and shows the presence of
three 50 kDa separate domains termed L, HN, and Hc [5–9]. The re-
cently solved structure of BoNT/E [10] shows the same domains
although arranged in a strikingly different way. The three-domains
structure is functional to the four steps of BoNTs’ cellular mode of
intoxication [11]: (a) binding carried out by domain Hc which con-
sists of two subdomains of equal size (25 kDa), termed Hc-N and
Hc-C; Hc-N is highly conserved among the different serotypes
whilst Hc-C is not [6]. A polysialoganglioside binding site has been
mapped in Hc-C, and is close to the binding site for the luminalon behalf of the Federation of Euro
ynaptic vesicle
ontecucco).domain of the synaptic vesicle (SV) protein synaptotagmin in
BoNT/B and /G [12–16]; the Hc-C of BoNT/A and /E contain, in
addition to the polysialoganglioside binding site a site of binding
for luminal loops of the SV protein SV2 [17–19]. (b) This double-
receptor binding mediates the next step which is the endocytosis
inside synaptic vesicles [16,20]. The interior of these vesicles
becomes acidic owing to the action of a vacuolar-type ATPase pro-
ton pump [21]. (c) Low pH induces a change in the conformation of
the HN domain which penetrates into the lipid bilayer and forms a
transmembrane channel which mediates the translocation of do-
main L from the vesicle lumen to the cytosol (third step) [22,23].
(d) The fourth step is the speciﬁc cleavage of one SNARE protein
at single and different peptide bonds by the seven L chains, which
are very speciﬁc metalloproteases [2–5].
Binding is the ﬁrst step in this chain of cellular events and it is a
highly critical one. In fact, though BoNTs remain in circulation in an
active form for many hours, after absorption from the intestine
[24,25], and therefore have a long time at their disposal to ﬁnd
peripheral nerve terminals, it should be considered that: (a) the
presynaptic cholinergic peripheral nerve terminals are a minute
proportion of the total cell surface exposed to the internal milieu
of the vertebrate body and (b) the inter-synaptic space is a rather
well protected anatomical site [26]. Moreover, an extensive clinical
experience indicates that BoNTs do not diffuse signiﬁcantly from
the injection site [27–29]. It should be additionally considered that
the mouse LD50 doses are close to 1015 M concentrations of BoNTpean Biochemical Societies.
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the body weight in mice). These facts suggest that BoNT should
bind to the presynaptic membrane very rapidly, with high afﬁnity
and speciﬁcity.
The presynaptic membrane is rich in negatively charged lipids
and glycoproteins, including the polysialoganglioside receptors
which project their negatively charged oligosaccharide portion at
a distance from the extracellular lipid bilayer surface [30–35].
Higly negatively charged complex gangliosides are not present
on the sarcolemma, i.e. the other side of the neuromuscular junc-
tion cleft [26,32,33] and this results in the fact that anti-complex
gangliosides syndromes such as Miller Fisher and Guillain-Barré
results are characterized by a speciﬁc attack of the presynaptic
membrane [36]. An even higher average distance from the presyn-
aptic surface is expected for the sialic acid residues attached to
abundant presynaptic proteins such as neurexophilins and neurex-
ins [37–39]. Therefore, an electric ﬁeld directed towards the mem-
brane is present on the external membrane surface, though its
value has never been estimated. Under these conditions, a protein
endowed with an electric dipole will reorient itself as it approaches
the membrane surface and will hit it with the positive side. In the
case of the BoNTs, if they are dipoles with the positive pole located
on the Hc domain, on approaching to the presynaptic membrane
they will reorient in such a way as to be in the most favourable po-
sition to bind to the exposed oligosaccharide head of the polysialo-
gangliosides. One cannot exclude that a BoNT molecule can do the
same with the facing sarcolemma membrane, but this membrane
is expected to be much less negative as it contains much less gan-
gliosides and lack the polysialic complex ones [32,33,36].
In the present paper, we have tested this possibility using the
known structures of BoNT/A, /B and /E and by modelling the 3D
structure of BoNT/C, /D, /E (for proper comparison), /F and /G on
them. We have then modelled the electrostatic ﬁeld at presynaptic
membranes as a ﬁxed potential difference at two opposite faces of
a cube enclosing the protein model. We have then rotated these
structures sampling the rotational conformational space and
recording the computed electrostatic energy. The results indicate
that electrostatics driven molecular reorientation of the toxin mol-
ecule on approaching the presynaptic membrane may well play an
important role in binding.2. Materials and methods
2.1. Molecular models
Structural models for BoNT/A, BoNT/B and BoNT/E were ob-
tained from the protein data bank [38,39] (PDB id. codes 3BTA,
1EPW and 3FFZ, respectively), for the L chain of other BoNTS we
used the data: PDB id. codes 2QNO, 2FPQ, 1ZQW, 2A8A ANS
1ZB7. Structural models for other BoNT serotypes were built by
homology as follows. MANIFOLD [40] was used to identify the bestTable 1
Correspondence between serotypes, accession numbers and models. The BoNT serotypes ar
The PDB accession number of the full structure (where available) and of the light chain are
between the modelled structure (where applicable) and corresponding comparative mode
Serotype Sequence (SWISS-PROT) Full structure (PDB) Light
A1 P10845 3BTA 1E1H
B P10844 1S0E, 1F31, 1EPW and others 1F82
C Q45849 n/a 2QN0
D P19321 n/a 2FPQ
E Q00496 n/a 1ZKW
F Q57236 n/a 2A8A
G Q60393 n/a 1ZB7template structure, several suboptimal alignments were computed
using a proﬁle–proﬁle method [41] and the structurally best align-
ment was chosen with FRST [42]. The models were generated by
comparative modelling using the HOMER server (http://pro-
tein.bio.unipd.it/homer/). Loops and side chains were modelled
with a fast divide and conquer method [43] and SCWRL [44],
respectively. Structural alignments between the X-ray crystallo-
graphic structures of all toxin serotype L chains and the models
were computed using CE [45] in order to validate the models. Table
1 contains information regarding the PDB codes of the proteins and
comparison between the present models and the experimental
structures. Hydrogens were added using the program pdb2gmx
distributed with the GROMACS package [46] and charges were as-
signed according to the Charmm forceﬁeld (version 27b) [47].
The structure of BoNT/E differs signiﬁcantly from BoNT/A and
BoNT/B, displaying a much more compact domains’ arrangement
[10] although the arrangement could be ﬂexible [48]. This makes
comparison with other BoNT’s difﬁcult because, for instance, when
the center of mass is set at a given distance from the model mem-
brane peripheral charges will be able to approach the membrane at
different closest distances and the resulting interactions will be
different owing to the damping effect of ionic strength. We will
consider therefore the homology model of BoNT/E for comparison
with other BoNT’s and consider in the end the results obtained on
the crystal structure of BoNT/E which however displays similar and
even more marked electrostatic features as those highlighted for
the other BoNT’s.
2.2. Membrane model and electrostatic calculations
The electrostatic ﬁeld associated to the membrane is difﬁcult to
model quantitatively because the charge density of the presynaptic
membrane is not known either locally or on average.
Due to the large curvature radius of the motoneuron presynap-
tic membrane, compared to typical molecular size, the electric ﬁeld
may be assumed, as a ﬁrst approximation, to be orthogonal to the
membrane surface. Moreover due to electroneutrality of the inner
part of the neuron it may be assumed that it is entirely determined
by the surface charge density on the outer membrane. We mod-
elled the membrane as a ﬂat surface with uniform charge density.
We followed a pragmatic approach in order to test, at least quali-
tatively, the effect of molecular orientation in the presence of an
electric ﬁeld. The molecule was enclosed in a cube of
200  200  200 Å3 with grid spacing 1 Å. Boundary conditions
on cube faces were set such that the potential U as a function of
z is:
Uz ¼ ðz zcmÞ  Ez ð1Þ
where zcm is the z-coordinate of the molecule center of mass, and Ez
is the electric ﬁeld (along the z-axis). With this choice the negative
potential face of the cube (representing a negatively charged mem-
brane) is an x–y plane at the bottom of the z-axis. The electric ﬁelde listed together with their corresponding sequence accession number in SWISS-PROT.
shown together with the sequence identity and root-mean-square-deviation (RMSD)
l.
chain (PDB) Template (PDB) Seq. id. (%) RMSD to light chain PDB
n/a 100 1.1
n/a 100 1.3
1S0E 34.2 1.8
1S0E 35.1 2.2
1S0E 37.9 1.9
1S0E 38.9 1.9
1S0E 57.7 1.4
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the membrane: 0.015 q/Å2, 0.005 q/Å2, 0.0015 q/Å2, corresponding
to electric ﬁelds of 3.5  108 V/m, 1.15  108 V/m, 3.5  107 V/m,
respectively. The ionic strength was set to 150 mM. All the mole-
cules were superposed on the structure of BoNT/A in order to have
a common frame of reference. The long axis of the molecules was
thus roughly aligned with the z-axis, i.e. with the direction of the
electric ﬁeld. The protein dimensions are approximately 80, 95
and 135 Å in the x-, y- and z-axis, respectively. The molecules were
rotated ﬁrst about the z-axis (in steps of 30) and then about the y-
axis (in steps of 30). In order to complete exploration of all possible
orientations a ﬁnal rotation around the z-axis should be applied, but
this was not necessary due to the electric ﬁeld symmetry about the
z-axis.
The Poisson–Boltzmann equation [49] was solved using the pro-
gram UHBD [50] employing standard parameters. For visualization
of the electrostatic potential, surfaces were generated with the
program MSMS [51] using a probe radius of 2.4 Å, larger than the
1.4 Å standard radius of water. This choice was motivated by the
rather large mesh (1.0 Å) employed for ﬁnite difference calcula-
tions for such a large system. Using a smaller radius implies that
the potential at the surface could be interpolated from points
mapped in or sensitive to the inner part of the solute, thus leading
to incorrect solution values. Visualization of surface potential and
isopotential curves was performed using the program DINO [52].3. Results and discussion
The present work is aimed at testing the possibility that BoNT
binding to the presynaptic membrane of neurons is greatly en-
hanced by the electrostatically driven reorientation of the BoNT
molecule as it approaches the external membrane surface. In fact,
this maximizes the possibility of BoNT membrane binding via its
Hc-C domain, which contains both the polysialoganglioside and
the SV protein binding sites. The 3D structure of BoNT/C, /D, /E,
/F and /G molecules were modelled onto the available 3D coordi-
nates of BoNT/A and /B. As a control of this operation we have com-
pared the 3D structure of the L chains obtained in this way with
those made available by X-ray crystallography (type E PDB code,
1T3A; type F PDB code, 2A8A; type G PDB code, 1ZB9). Table 1
shows that there is an almost complete overlapping of the poly-
peptide chains and lateral chains and therefore we have proceeded
with the computation of the energy of the molecules in the pres-
ence of an electrostatic ﬁeld according to the model described in
the Section 2.
The difference in energy between the most favourable and most
unfavourable orientations for BoNT/A was roughly proportional to
the applied electric ﬁeld, ranging from 1.6 to 16 kcal/mol depend-
ing on the intensity of the electric ﬁeld. These ﬁgures depend on
the size of the simulation box and on the electric ﬁeld model
adopted; nevertheless, these effects should be greatly magniﬁed
when the protein approaches the membrane within few Debye
lengths (8 Å for the ionic strength employed) where ionic solvent
screening is reduced. We then set the electric ﬁeld at 3.5  108
V/m and performed calculations for all molecular models after
superposition on BoNT/A for setting a common frame of reference.
The difference in interaction energies between most favourable
and most unfavourable orientation were found to be: BoNT/A
9.7 kcal/mol, BoNT/B 2.5 kcal/mol, BoNT/C 3.9 kcal/mol,
BoNT/D 5.4 kcal/mol, BoNT/E (homology model) 10.7 kcal/mol,
BoNT/F 9.3 kcal/mol, BoNT/G 4.3 kcal/mol. For all these models
the most favourable orientation had the binding domain oriented
towards the membrane surface at negative potential. It is interest-
ing to note that this is consistent with the overall dipole of the
molecules whose direction in the most favourable orientation isco-linear (within 30) with the axis of the electric ﬁeld. For
BoNT/G two opposite orientations, one of the two being similar
to those of other BoNTs, have almost the same interaction energy,
pointing out that in this case electrostatic effects are not clearly
determining the orientation of the molecule close to the charged
surface. It is noteworthy that BoNT/G is the least toxic of all BoNTs
[53] and this orientation uncertainty may well contribute to its
lower toxicity.
In order to further detail this picture, the electrostatic potential
at the molecular surface (displayed using a surface probe radius of
2.4 Å in order to avoid any problem due to the coarse mesh em-
ployed in the computation) and the isopotential surfaces displayed
at 0.3 kcal/(mol n q) (blue), 0.3 kcal/(mol n q) (red) and
0.01 kcal/(mol n q) (white) are shown in Fig. 1. The models inter-
acting more strongly with the charged negative surfaces are those
characterized by the presence of a positive potential surface at the
binding domain and by the presence of an extended positive elec-
trostatic ﬁeld as evidenced by the reduced presence of close to zero
isopotential surface (white surfaces in Fig. 1). This is more evident
for the models BoNT/A and BoNT/F and, to a lower extent, for
BoNT/E (homology model) which is however also characterized, to-
gether with BoNT/A, by one of the lowest negative charges among
the molecules considered. The overall conservation of an excess of
positive charges at the Hc-C domain is conﬁrmed by the analysis of
all the 79 sequences aligned for this domain in the Pfam database
[54]. Indeed the putative charge of the sequence, computed as the
difference between basic and acidic residues, is ranging from 0 to
10 with an average charge of 5.1 ± 2.4. A similar positive charge
conservation is not found in the other three BoNT domains re-
corded in Pfam.
The same calculations have been repeated for the crystal struc-
ture of BoNT/E (PDB id code: 3FFZ). Here the catalytic and binding
domain are on the same side with respect to the translocation do-
main. The electrostatic potential at the ganglioside binding site,
which is found on an edge of the molecule, is strongly positive.
Compared to other BoNT’s, however, a large area at positive poten-
tial is present that entails mostly the binding domain, but also part
of the translocation helix and part of the catalytic domain. As a re-
sult the most favourable orientation in the presence of the electric
ﬁeld is broader, but still oriented as to bring the ganglioside bind-
ing site close to the negatively charged membrane. The magnitude
of the interaction energy is strongly reduced because of the larger
distance from the membrane due to more compact shape of the
protein.
The present calculations and results indicate that electrostatic
interactions play an important role in the presynaptic membrane
binding of the BoNTs. These molecules are electric dipoles with a
concentration of positively charged residues localized around the
Hc-C terminal domain of the molecule, which contains both the
polysialoganglioside and the SV protein binding sites. In particular,
the G1b series of gangliosides which are speciﬁcally bound by these
neurotoxins [12,17,19] contain from 2 to 4 sialic acid residues
which project several Å from the outer lipid monolayer of the pre-
synaptic membrane and, for this reason, were suggested to act as a
sort of presynaptic membrane antennae [55]. The G1b binding site
is at the tip of the Hc-C domain and the distribution of the positive
charges on the BoNTs molecules is such that almost all hits of the
BoNT molecule with the presynaptic membrane will result in bind-
ing the oligosaccharide head of the G1b receptor molecule. In other
words, on the basis of the present ﬁndings, the rate of binding of
BoNT to the nerve terminal is expected to be controlled only by
its rate of diffusion in the tissue ﬂuids. Extrapolating the data ob-
tained with the GM1 [30] to the G1b gangliosides, the high concen-
tration of gangliosides on the presynaptic membrane may act as a
sort of trap for any BoNT molecule that happens to reach a cholin-
ergic nerve terminal. This event is expected to be rare on the basis
Fig. 1. For each type of Botulinum Neurotoxin (BoNT/A to /G) four views are shown with their surface electrostatic potential contour (lower panel). The four views are along
negative z-axis, positive z-axis, positive x-axis and negative x-axis, respectively. Blue is saturated at +1.5 kcal/(mol n q), red is saturated at 1.5 kcal/(mol n q). These views
roughly correspond to the best-energy orientation when a hypothetical charged membrane is located at the bottom of the ﬁgure, parallel to the z–x plane (upper panel).
Electrostatic isopotential surfaces in the neighbour of the molecule. Orientation and views are as for the upper panel. Blue refers to 0.3 kcal/(mol n q), red refers to 0.3 kcal/
(mol n q) and white refers to 0.01 kcal/(mol n q).
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autonomic nerve terminals, but this would be compensated by
an electrostatically driven membrane binding to polysialoganglio-
sides, followed by further binding to other membrane receptors
which predispose and mediate the entry of the toxin into the nerve
terminal [55,56].
The present ﬁndings are derived from an analysis of the struc-
ture of the seven BoNTs, but they may well be relevant for many
other charged ligands that interact with the plasma membrane of
a variety of cells. Although a comprehensive analysis of a large
number of toxins is beyond the scope of the present work, it is
worth mentioning that another important toxin, the cholera toxinwhich binds also a ganglioside receptor conﬁrm this picture. The
results obtained on the pentamer structure after removal of the
bound gangliosides (PDB id. code: 2CHB) shows a strong electro-
static potential polarity with the binding face at strong positive po-
tential and the other at negative potential.Acknowledgements
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